| Autor: |
Peron JP; Neuroimmune Interactions Laboratory, Department of Immunology, Institute of Biomedical Sciences, University of Sao Paulo, São Paulo, SP, Brazil., de Brito AA; Laboratory of Pulmonary and Exercise Immunology-LABPEI, Nove de Julho University (UNINOVE), São Paulo, SP, Brazil., Pelatti M; Division of Human Genome Research Center, Biosciences Institute, University of São Paulo, São Paulo, SP, Brazil., Brandão WN; Neuroimmune Interactions Laboratory, Department of Immunology, Institute of Biomedical Sciences, University of Sao Paulo, São Paulo, SP, Brazil., Vitoretti LB; Laboratory of Pulmonary and Exercise Immunology-LABPEI, Nove de Julho University (UNINOVE), São Paulo, SP, Brazil., Greiffo FR; Laboratory of Pulmonary and Exercise Immunology-LABPEI, Nove de Julho University (UNINOVE), São Paulo, SP, Brazil., da Silveira EC; Laboratory of Pulmonary and Exercise Immunology-LABPEI, Nove de Julho University (UNINOVE), São Paulo, SP, Brazil., Oliveira-Junior MC; Division of Human Genome Research Center, Biosciences Institute, University of São Paulo, São Paulo, SP, Brazil., Maluf M; CEERH-Specialized Center for Human Reproduction, Division of Reproductive Medicine, São Paulo, SP, Brazil., Evangelista L; Division of Reproductive Medicine-Célula Mater, São Paulo, SP, Brazil., Halpern S; Division of Reproductive Medicine-Célula Mater, São Paulo, SP, Brazil., Nisenbaum MG; Division of Reproductive Medicine-Célula Mater, São Paulo, SP, Brazil., Perin P; CEERH-Specialized Center for Human Reproduction, Division of Reproductive Medicine, São Paulo, SP, Brazil., Czeresnia CE; Division of Reproductive Medicine-Célula Mater, São Paulo, SP, Brazil., Câmara NO; Laboratory of Transplantation Immunobiology, Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, SP, Brazil., Aimbire F; Department of Science and Technology, Federal University of São Paulo, São José dos Campos, SP, Brazil., Vieira RP; Division of Human Genome Research Center, Biosciences Institute, University of São Paulo, São Paulo, SP, Brazil., Zatz M; Laboratory of Pulmonary and Exercise Immunology-LABPEI, Nove de Julho University (UNINOVE), São Paulo, SP, Brazil., de Oliveira AP; Division of Human Genome Research Center, Biosciences Institute, University of São Paulo, São Paulo, SP, Brazil. |
| Abstrakt: |
Cigarette smoke-induced chronic obstructive pulmonary disease is a very debilitating disease, with a very high prevalence worldwide, which results in a expressive economic and social burden. Therefore, new therapeutic approaches to treat these patients are of unquestionable relevance. The use of mesenchymal stromal cells (MSCs) is an innovative and yet accessible approach for pulmonary acute and chronic diseases, mainly due to its important immunoregulatory, anti-fibrogenic, anti-apoptotic and pro-angiogenic. Besides, the use of adjuvant therapies, whose aim is to boost or synergize with their function should be tested. Low level laser (LLL) therapy is a relatively new and promising approach, with very low cost, no invasiveness and no side effects. Here, we aimed to study the effectiveness of human tube derived MSCs (htMSCs) cell therapy associated with a 30mW/3J-660 nm LLL irradiation in experimental cigarette smoke-induced chronic obstructive pulmonary disease. Thus, C57BL/6 mice were exposed to cigarette smoke for 75 days (twice a day) and all experiments were performed on day 76. Experimental groups receive htMSCS either intraperitoneally or intranasally and/or LLL irradiation either alone or in association. We show that co-therapy greatly reduces lung inflammation, lowering the cellular infiltrate and pro-inflammatory cytokine secretion (IL-1β, IL-6, TNF-α and KC), which were followed by decreased mucus production, collagen accumulation and tissue damage. These findings seemed to be secondary to the reduction of both NF-κB and NF-AT activation in lung tissues with a concomitant increase in IL-10. In summary, our data suggests that the concomitant use of MSCs + LLLT may be a promising therapeutic approach for lung inflammatory diseases as COPD. |
